XLO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XLO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xilio Therapeutics's enterprise value is $-8.31 Mil. Xilio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was $-58.00 Mil. Therefore, Xilio Therapeutics's EV-to-EBITDA for today is 0.14.
The historical rank and industry rank for Xilio Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 6 years, the highest EV-to-EBITDA of Xilio Therapeutics was 0.34. The lowest was -0.50. And the median was -0.03.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2025-05-04), Xilio Therapeutics's stock price is $0.7502. Xilio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.280. Therefore, Xilio Therapeutics's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Xilio Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics Annual Data | |||||||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | - | -3.54 | 0.31 | 0.22 | 0.06 |
Xilio Therapeutics Quarterly Data | |||||||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EV-to-EBITDA | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.22 | -0.17 | 0.38 | 0.29 | 0.06 |
For the Biotechnology subindustry, Xilio Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's EV-to-EBITDA falls into.
Xilio Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -8.308 | / | -58.001 | |
= | 0.14 |
Xilio Therapeutics's current Enterprise Value is $-8.31 Mil.
Xilio Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics (NAS:XLO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xilio Therapeutics's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 0.7502 | / | -1.280 | |
= | At Loss |
Xilio Therapeutics's share price for today is $0.7502.
Xilio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Xilio Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Katarina Luptakova | officer: Chief Medical Officer | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Christopher James Frankenfield | officer: Chief Operating Officer | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Kevin M. Brennan | officer: SVP, FINANCE AND ACCOUNTING | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Edward C English | officer: Principal Accounting Officer | 828 WINTER STREET, WALTHAM MA 02451 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Robert W. Ross | director | C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139 |
Yuan Xu | director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Bain Capital Life Sciences Fund Ii, L.p. | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Atlas Venture Opportunity Fund I, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Sv7 Impact Medicine Fund Lp | 10 percent owner | 71 KINGSWAY, LONDON X0 WC2B 6ST |
Bcls Ii Investo (gp), Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bcls Ii Investco, Lp | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bain Capital Life Sciences Investors Ii, Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Rivervest Venture Fund Iv, L.p. | 10 percent owner | 101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105 |
From GuruFocus
By Marketwired • 01-17-2025
By GlobeNewswire • 01-17-2025
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 02-03-2025
By Marketwired • 10-02-2024
By GlobeNewswire • 09-27-2023
By Marketwired • 03-11-2025
By Marketwired • 04-04-2025
By Marketwired • 08-08-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.